Everything below concerns Ac-SDKP. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
== History == Dantrolene was first described in the scientific literature in 1967, as one of several hydantoin derivatives proposed as a new class of muscle relaxant. Dantrolene underwent extensive further development, and its action on skeletal muscle was described in detail in 1973. Dantrolene was widely used in the management of spasticity before its efficacy in treating malignant hyperthermia was discovered by South African anesthesiologist Gaisford Harrison and reported in a landmark 1975 article published in the British Journal of Anaesthesia. Harrison experimentally induced malignant hyperthermia with halothane anesthesia in genetically susceptible pigs, and obtained an 87.5% survival rate, where seven of his eight experiments survived after intravenous administration of dantrolene. The efficacy of dantrolene in humans was later confirmed in a large, multicenter study published in 1982, and confirmed epidemiologically in 1993. Before dantrolene, the only available treatment for malignant hyperthermia was either procainamide or procaine, the latter being associated with a 60% mortality rate in animal models.
These illicit pills often contain "a mix of amphetamines, caffeine and various fillers", which are sometimes referred to as "captagon" (with a lowercase "c"). According to some leaks, militant groups export the drug in exchange for weapons and cash. According to Abdelelah Mohammed Al-Sharif, secretary general of the National Committee for Narcotics Control and assistant director of Anti-Drug and Preventative Affairs, forty percent of users between the ages of twelve and twenty-two in Saudi Arabia are addicted to fenethylline. In 2017, fenethylline was the most popular recreational drug in the Arabian Peninsula. In October 2015, a member of the Saudi royal family, Prince Abdel Mohsen Bin Walid Bin Abdulaziz, and four others were detained in Beirut on charges of drug trafficking after airport security discovered two tons of fenethylline pills and some cocaine on a private jet scheduled to depart for Riyadh, the capital of Saudi Arabia. The following month, Agence France-Presse reported that Turkish authorities had seized two tonnes of fenethylline—about eleven million pills—during raids in the Hatay region on the Syrian border. The pills had been produced in Syria and were being shipped to countries in the Arab states of the Persian Gulf. In December 2015, the Lebanese Army announced that it had discovered two large-scale drug production workshops in the north of the country and seized large quantities of fenethylline pills. Two days earlier, three tons of fenethylline and hashish were seized at Beirut Airport, concealed in school desks being exported to Egypt.
For this reason, the elasticity of the ECM or another binding substrate is very important. The tension created by a cell pulling against a stiff substrate needs to reach a certain threshold to allow for mechanotaxis to occur.
=== Physical forces === Proper storage in secure and stable shelving will allow for less stress and movement to affect plant collections. Dried and pressed plant specimens can be stored best in archival-grade boxes, or tied in bundles in cardboard folders for long-term storage. For collections that may be handled more frequently, specimens can be placed in archival-grade plastic sheets placed in ring folders.
The Gospels of Matthew, Mark and Luke state that Joseph of Arimathea wrapped the body of Jesus in a "linen cloth" or "linen shroud" or just in "linen" (Greek: sindon) and placed it in a new tomb. The Gospel of John says that the body was wrapped in linen cloths (Greek: othonia), with a significant quantity of myrrh and aloes. The Gospel of John states that after the Resurrection of Jesus, "Simon Peter came, following him, and went into the tomb. He saw the linen wrappings lying there, and the cloth that had been on Jesus's head, not lying with the linen wrappings but rolled up in a place by itself." The Gospel of Luke states: "But Peter got up and ran to the tomb; stooping and looking in, he saw the linen cloths by themselves; then he went home, amazed at what had happened." In 1543, John Calvin, in his book Treatise on Relics, explained why the Shroud cannot be genuine:
Sources: en.wikipedia.org
Another dimension to the tactical use of nuclear weapons is that of such weapons deployed at sea for use against surface and submarine vessels. Until 1992, vessels of the United States Navy (and their aircraft) deployed various such weapons as bombs, rockets (guided and unguided), torpedoes, and depth charges. Such tactical naval nuclear weapons were considered more acceptable to use early in a conflict because there would be few civilian casualties. It was feared by many planners that such use would probably quickly have escalated into a large-scale nuclear war. This situation was particularly exacerbated by the fact that such weapons at sea were not constrained by the safeguards provided by the Permissive Action Link attached to U.S. Air Force and Army nuclear weapons. It is unknown if the navies of the other nuclear powers yet today deploy tactical nuclear weapons at sea. The 2018 US Nuclear Posture Review emphasised the need for the US to have sub-strategic nuclear weapons as additional layers for its nuclear deterrence.
== Research == There is little evidence that turkey tail mushroom extracts or PSK are useful for treating cancer or any medical condition. Polysaccharide-K, an extract of T. versicolor, is approved in Japan as an adjuvant therapy in cancer treatment.
In this process, acetonitrile functions both as solvent and nitrogen source and is converted into acetic acid. The reaction proceeds via multiple Mumm rearrangements. Alcohols can be transformed into nitriles by a Mitsunobu reaction, employing cyanomethylidene trimethyl phosphorane in the presence of acetone cyanohydrin. N-Alkylamides can be converted to nitriles via the von Braun degradation using phosphorus pentachloride. Alternative reagents include phosphorus pentabromide and carbonyl bromide.
Texts on Wikisource: Chisholm, Hugh, ed. (1911). "Amines" . Encyclopædia Britannica (11th ed.). Cambridge University Press. Synthesis of amines Factsheet, amines in food Archived 19 February 2018 at the Wayback Machine
Committee on Herbal Medicinal Products (HMPC) (22 May 2012). "Assessment report on Citrus bergamia Risso et Poiteau, aetheroleum Final" (PDF). European Medicines Agency (EMA). Archived from the original (PDF) on 8 April 2014. Retrieved 7 April 2014. Committee on Herbal Medicinal Products (HMPC) (22 May 2012). "List of references supporting the assessment of Citrus bergamia Risso et Poiteau, aetheroleum Final" (PDF). European Medicines Agency (EMA). Archived from the original (PDF) on 8 April 2014. Retrieved 7 April 2014.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.